Ann: Extension of Entitlement Issue Closing Date, page-110

First 110 Last

Share
Profile

Follow
Jalana

535 Posts.

308

06/12/18

15:10

Post #: 36773094
Share

Originally posted by DoubleDown!: ↑

Norwood have called half a dozen or so trading halts in the last couple of years. Mostly for CR but also to announce the Affinion 'deal'.

It's hard to estimate the importance of the deal from that fact alone. The $35k deal was just announced, so you could assume it's bigger than that.

But then again Norwood is on its knees with an extended CR that potentially has no underwriter and they have run out of money. So they need retailers to throw money at them to survive and this particular announcement with a halt creates that scenario.

I'm strongly suspicious of this deal coming the afternoon it was needed for rights holders to face the choice of missing out or going in blind.

After what holders have been through if Paul is playing funny buggers now, well that's just brutal.

I just can't see a telco throwing millions of dollars at Norwood, certainly not upfront. They'd run the risk of losing most of it before their service was delivered.

I think it will be some sort of trial and I think it will fall into the $50-200k range for a few months and I think it will be similar to Thomas Cook requiring users to opt in/sign up rather than pushed on them. I think it's very likely to be WV orientated.

Time will tell, good luck to holders. I just hope PO isn't being his usual investor loathing self.

Expand

"After what holders have been through if Paul is playing funny buggers now, well that's just brutal."
"Time will tell, good luck to holders. I just hope PO isn't being his usual investor loathing self".

Spot on dd. Needed to be highlighted.

NOR Price at posting: 0.4¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 1 more message in this thread...

First 110 Last

Add NOR (ASX) to my watchlist

(20min delay)
Last 3.8¢		Change 0.000(0.00%)		Mkt cap ! $18.09M

Open	High	Low	Value	Volume
3.7¢	3.8¢	3.7¢	$108	2.88K

Buyers (Bids)

No.	Vol.	Price($)
3	236234	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
4.0¢	200000	1

View Market Depth

No.	Vol.	Price($)
3	236234	0.030
1	50000	0.029
1	120700	0.028
1	150000	0.027
5	550000	0.026

Price($)	Vol.	No.
0.040	200000	1
0.042	23833	1
0.045	1534501	2
0.046	21759	1
0.055	18199	1

Last trade - 15.33pm 07/10/2024 (20 minute delay)

NOR (ASX) Chart

Ann: Extension of Entitlement Issue Closing Date, page-110

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Extension of Entitlement Issue Closing Date, page-110

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News